Status:

COMPLETED

Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus

Lead Sponsor:

Vanderbilt University

Conditions:

Obese Patients

Type 2 Diabetes Mellitus

Eligibility:

All Genders

18-60 years

Phase:

PHASE3

Brief Summary

Central hypothesis is: Gastric bypass surgery reduces the risk of CVD in morbidly obese subjects (defined as BMI ≥35 kg/m2) with T2DM. To determine whether surgically induced weight loss decreases th...

Detailed Description

Patients with type 2 diabetes mellitus (T2DM) are more likely to die from cardiovascular diseases (CVD) than people without diabetes. Furthermore, patients with diabetes have not benefited from the ad...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of T2DM diabetes mellitus with HbA1c ≤ 10.0%
  • Any one of the following will be considered to be sufficient evidence that diabetes is present:
  • Current regular use of insulin
  • Current regular use of oral hypoglycemic medication.
  • Documented diabetes by current ADA criteria (98).
  • Body mass index ≥ 35 kg/m2 in accord with the 1991 NIH obesity surgery consensus conference criteria and stable weight for the previous 3 months (99).
  • Age between 18-60 years old. Individuals older than 60 years of age are excluded due to their increased risk of mortality and peri-operative morbidity.
  • Ability and willingness to provide informed consent.
  • No expectation that subject will be moving out of the area of the clinical center during the next 24 months.

Exclusion

  • Presence of CVD defined as: CAD, electrocardiographic criteria for past myocardial infarction(s), ischemic stroke, peripheral artery bypass surgery, percutaneous transluminal angioplasty, or amputation because of atherosclerotic disease.
  • Significant non-diabetic co-morbidity affecting life expectancy (e.g., malignancy).
  • Significant other co-morbidities (e.g. psychiatric disorder) that results in ineligibility for gastric bypass surgery.
  • Pregnancy or planning pregnancy.
  • Severe dyslipidemia (triglycerides \>600 mg/dl or cholesterol \>350 mg/dl).
  • Uncontrolled hypertension.
  • Smoking.

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2009

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT00444392

Start Date

March 1 2007

End Date

March 1 2009

Last Update

November 21 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232